What is Adicet Bio, Inc.'s earnings per share (EPS)?

Adicet Bio, Inc. (ACET) reported diluted earnings per share of -$16.95 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Adicet Bio, Inc. (ACET) Financials

ACET

FY2025 annual

Net Income -$116.8M +0.3% YoY

EPS (Diluted) -$16.95 YoY not available

Free Cash Flow -$97.0M -3.7% YoY

Operating Cash Flow -$95.2M -3.1% YoY

Market Cap $58.5M as of Oct 6, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 0.5x on $120.1M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 6, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 5, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ACET SEC filings page.

This page shows Adicet Bio, Inc. (ACET) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ACET FY2025 2026-10-04

Adicet remains a development-stage business: research spending drives recurring cash use, while financing rather than debt supports the balance sheet.

In FY2025, R&D spending was $99.1M, nearly matching operating cash flow of -$95.2M. That relationship persisted from FY2024, when R&D was $99.3M and operating cash flow was -$92.4M, pointing to a research-led cost base rather than a one-year spending spike.

FY2025 liabilities were $33.1M against $192.4M of assets, so reported financing is weighted toward equity rather than debt. Debt-to-equity was 0.2x, indicating liabilities are not the main funding source.

The reported liquidity comparison was 20 months of the latest annual operating outflow, while financing cash flow supplied $75.2M in FY2025. Alongside operating cash flow of -$95.2M, this indicates financing activities supplemented operations as a source of cash during the year.

Financial Health Signals

Financial health score not available

Adicet Bio, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/6

Adicet Bio, Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

Adicet Bio, Inc. reported a net loss of $116.8M while operations used $95.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Adicet Bio, Inc. reported an operating loss of $122.1M against $36K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$21.1M

YoY+31.5%

QoQ-4.3%

Adicet Bio, Inc.'s EBITDA was -$21.1M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 31.5% from the same quarter a year earlier. Against the prior quarter it is down 4.3%.

Net Income

-$21.4M

YoY+31.6%

QoQ-5.5%

Adicet Bio, Inc. reported -$21.4M in net income in Q2 2026. This represents an increase of 31.6% from the same quarter a year earlier. Against the prior quarter it is down 5.5%.

EPS (Diluted)

-$1.99

QoQ-5.9%

Adicet Bio, Inc. earned -$1.99 per diluted share (EPS) in Q2 2026. Against the prior quarter it is down 5.9%.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$20.0M

YoY+24.9%

QoQ+7.0%

Adicet Bio, Inc. recorded an outflow of $20.0M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 24.9% from the same quarter a year earlier. Against the prior quarter it is up 7.0%.

Cash & Debt

$33.1M

YoY-4.6%

QoQ-8.6%

5Y CAGR-30.8%

Adicet Bio, Inc. held $33.1M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

QoQ+0.1%

5Y CAGR-21.7%

Adicet Bio, Inc. had 9M shares outstanding in Q2 2026. Against the prior quarter it is up 0.1%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-17.8%

YoY+5.6pp

QoQ-3.3pp

Adicet Bio, Inc.'s ROE was -17.8% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 5.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.3 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$18.4M

YoY-35.1%

QoQ+5.5%

Adicet Bio, Inc. invested $18.4M in research and development in Q2 2026. This represents a decrease of 35.1% from the same quarter a year earlier. Against the prior quarter it is up 5.5%.

Capital Expenditures

$202K

YoY+329.8%

QoQ+445.9%

5Y CAGR-37.6%

Adicet Bio, Inc. invested $202K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 329.8% from the same quarter a year earlier. Against the prior quarter it is up 445.9%.

Share Buybacks

Not reported for Q2 2026.

ACET Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ACET quarterly income statement

Metric	TTM	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K
R&D Expenses	N/A	$99.1M-0.2%	$99.3M-6.3%	$106.0M+48.8%	$71.2M+45.6%	$48.9M+42.5%	$34.3M+44.9%	$23.7M+61.0%	$14.7M-12.6%	$16.8M
SG&A Expenses	N/A	$23.0M-18.8%	$28.3M+6.6%	$26.5M+0.9%	$26.3M+18.3%	$22.2M-2.4%	$22.8M+161.8%	$8.7M+3.1%	$8.4M+312.5%	$2.0M
Operating Income	N/A	-$122.1M+4.3%	-$127.6M+16.1%	-$152.0M-109.6%	-$72.6M-18.1%	-$61.4M-56.8%	-$39.2M-24.9%	-$31.4M-109.8%	-$15.0M+20.7%	-$18.9M
EBITDA	N/A	-$115.7M+4.5%	-$121.1M+17.0%	-$145.9M-108.6%	-$70.0M-16.8%	-$59.9M-57.8%	-$38.0M-25.9%	-$30.1M-119.4%	-$13.7M+27.2%	-$18.9M
Interest Expense	N/A	$36K+800.0%	$4K-84.0%	$25K-68.8%	$80K-54.5%	$176K+31.3%	$134K	N/A	N/A	N/A
Income Tax	N/A	$0	$0	$0	$0+100.0%	-$125K+95.6%	-$2.8M-14915.8%	$19K+103.2%	-$589K	$0
Net Income	N/A	-$116.8M+0.3%	-$117.1M+17.9%	-$142.7M-104.4%	-$69.8M-12.6%	-$62.0M-69.0%	-$36.7M-30.4%	-$28.1M-202.6%	-$9.3M+72.5%	-$33.8M
EPS (Basic)	N/A	-$16.95+20.5%	-$21.33-544.4%	-$3.31-94.7%	-$1.70+15.0%	-$2.00	N/A	N/A	N/A	N/A
EPS (Diluted)	—	-$16.95	-$21.33	-$3.31	-$1.70+15.0%	-$2.00	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	7M	5M	43M	41M+32.7%	31M	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
R&D Expenses	$18.4M-35.1%	$17.5M-23.3%	N/A	$22.9M-13.0%	$28.4M+9.7%	$22.8M-4.5%	N/A	$26.3M+0.3%
SG&A Expenses	$3.9M-2.9%	$4.1M-42.3%	N/A	$5.1M-26.1%	$4.0M-42.9%	$7.1M+1.4%	N/A	$6.9M+4.0%
Operating Income	-$22.3M+31.2%	-$21.6M+27.8%	N/A	-$28.0M+15.7%	-$32.4M+1.4%	-$29.9M+3.2%	N/A	-$33.2M+36.6%
EBITDA	-$21.1M+31.5%	-$20.2M+28.5%	N/A	-$26.4M+16.5%	-$30.8M+1.5%	-$28.3M+3.2%	N/A	-$31.6M+37.7%
Interest Expense	$22K	$23K	N/A	$12K+1100.0%	$0	$0-100.0%	N/A	$1K0.0%
Income Tax	$143K	$0	N/A	$0	$0	$0	N/A	$0
Net Income	-$21.4M+31.6%	-$20.2M+28.2%	N/A	-$26.9M+11.9%	-$31.2M-4.4%	-$28.2M-0.7%	N/A	-$30.5M+38.9%
EPS (Basic)	-$1.99+63.7%	-$1.88+62.1%	-$16.01-5064.5%	-$0.29+14.7%	-$5.48-1560.6%	-$4.96-1317.1%	-$0.31+54.4%	-$0.34+70.7%
EPS (Diluted)	-$1.99	-$1.88	-$16.01	-$0.29	-$5.48	-$4.96	-$0.31+54.4%	-$0.34
Diluted Shares (Avg)	11M	11M	N/A	91M	6M	6M	N/A	91M

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.

ACET Balance Sheet

ACET quarterly balance sheet

Metric	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K
Total Assets	$192.4M-12.7%	$220.2M+6.2%	$207.3M-37.3%	$330.7M-2.4%	$338.9M+120.3%	$153.8M+88.6%	$81.6M-25.8%	$109.9M+99.2%	$55.2M
Current Assets	$160.9M-10.7%	$180.1M+11.0%	$162.3M-37.8%	$261.0M-7.6%	$282.4M+181.5%	$100.3M+56.3%	$64.2M-41.4%	$109.5M+98.6%	$55.2M
Cash & Equivalents	$38.9M-31.1%	$56.5M-64.6%	$159.7M-38.0%	$257.7M-7.2%	$277.5M+229.1%	$84.3M+695.0%	$10.6M+11.9%	$9.5M-82.2%	$53.3M
Short-Term Investments	$119.6M-0.2%	$119.8M	$0	$0	$0-100.0%	$10.3M-80.1%	$51.8M	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0-100.0%	$10.6M	$0	$0
Goodwill	N/A	N/A	$0-100.0%	$19.5M0.0%	$19.5M-3.1%	$20.1M	N/A	N/A	N/A
Total Liabilities	$33.1M-1.4%	$33.6M-9.5%	$37.1M-3.2%	$38.4M+7.1%	$35.8M-18.6%	$44.0M-69.0%	$142.0M-1.0%	$143.5M+74.6%	$82.1M
Current Liabilities	$21.5M+11.0%	$19.4M+0.5%	$19.3M-2.1%	$19.7M+20.8%	$16.3M-27.4%	$22.5M+51.2%	$14.9M+160.1%	$5.7M+3.9%	$5.5M
Non-Current Liabilities	$11.6M-18.3%	$14.2M-20.3%	$17.8M-4.4%	$18.6M-4.3%	$19.5M-9.5%	$21.5M-83.1%	$127.1M-7.7%	$137.7M+79.7%	$76.6M
Total Equity	$159.2M-14.7%	$186.6M+9.7%	$170.2M-41.8%	$292.3M-3.6%	$303.1M+176.0%	$109.8M+281.9%	-$60.4M-80.1%	-$33.5M-24.4%	-$26.9M
Retained Earnings	-$614.7M-23.5%	-$497.9M-30.8%	-$380.8M-59.9%	-$238.1M-41.5%	-$168.3M-58.3%	-$106.3M-52.7%	-$69.6M+2.4%	-$71.4M-111.4%	-$33.8M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$148.2M-9.1%	$169.4M-11.4%	$192.4M-12.7%	$140.5M-42.9%	$163.0M-39.4%	$191.3M-34.7%	$220.2M+6.2%	$246.0M+5.4%
Current Assets	$120.8M-5.5%	$140.1M-8.8%	$160.9M-10.7%	$106.5M-48.4%	$127.7M-44.1%	$153.6M-38.7%	$180.1M+11.0%	$206.3M+11.0%
Cash & Equivalents	$33.1M-4.6%	$36.2M+28.8%	$38.9M-31.1%	$29.1M-72.4%	$34.7M-84.5%	$28.1M-82.4%	$56.5M-64.6%	$105.5M-42.4%
Short-Term Investments	$85.1M-5.7%	$101.3M-17.1%	$119.6M-0.2%	$74.0M-23.4%	$90.2M	$122.3M	$119.8M	$96.6M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$28.0M-5.3%	$29.3M-1.7%	$33.1M-1.4%	$31.3M-9.0%	$29.6M-12.2%	$29.8M-13.0%	$33.6M-9.5%	$34.4M-10.8%
Current Liabilities	$18.0M+5.4%	$18.3M+11.3%	$21.5M+11.0%	$18.9M-2.3%	$17.1M-4.6%	$16.4M-5.8%	$19.4M+0.5%	$19.4M-1.9%
Non-Current Liabilities	$10.0M-19.9%	$11.0M-17.6%	$11.6M-18.3%	$12.4M-17.6%	$12.5M-20.9%	$13.4M-20.5%	$14.2M-20.3%	$15.0M-20.1%
Total Equity	$120.1M-9.9%	$140.1M-13.2%	$159.2M-14.7%	$109.1M-48.4%	$133.4M-43.3%	$161.4M-37.6%	$186.6M+9.7%	$211.5M+8.7%
Retained Earnings	-$656.3M-17.8%	-$634.9M-20.7%	-$614.7M-23.5%	-$584.2M-24.5%	-$557.3M-27.0%	-$526.1M-28.7%	-$497.9M-30.8%	-$469.2M-33.6%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

ACET Cash Flow Statement

ACET quarterly cash flow statement

Metric	TTM	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K
Operating Cash Flow	-$84.5M	-$95.2M-3.1%	-$92.4M+1.4%	-$93.7M-109.4%	-$44.8M+12.3%	-$51.1M-22.9%	-$41.6M-49.0%	-$27.9M-53.4%	-$18.2M-65.5%	-$11.0M
Depreciation & Amortization	N/A	$6.4M-1.3%	$6.5M+6.1%	$6.1M+136.8%	$2.6M+67.4%	$1.5M+25.4%	$1.2M-1.0%	$1.2M+1.3%	$1.2M+24340.0%	$5K
Stock-Based Compensation	N/A	$14.3M-35.8%	$22.2M+9.7%	$20.3M+18.3%	$17.1M+36.9%	$12.5M+137.7%	$5.3M+347.9%	$1.2M-52.6%	$2.5M+427.4%	$470K
Capital Expenditures	$438K	$1.7M+55.5%	$1.1M-75.0%	$4.5M-73.4%	$16.8M+28.6%	$13.0M+1217.8%	$990K-7.5%	$1.1M+22.1%	$876K+1890.9%	$44K
Free Cash Flow	-$85.0M	-$97.0M-3.7%	-$93.5M+4.8%	-$98.2M-59.5%	-$61.5M+4.0%	-$64.1M-50.7%	-$42.5M-46.9%	-$29.0M-51.9%	-$19.1M-72.8%	-$11.0M
Investing Cash Flow	$7.8M	$2.4M+102.0%	-$119.2M-2571.2%	-$4.5M+73.4%	-$16.8M-500.2%	-$2.8M-102.4%	$115.2M+340.4%	-$47.9M-198.5%	-$16.1M-36395.5%	-$44K
Financing Cash Flow	$75.1M	$75.2M-32.4%	$111.3M+47064.0%	$236K-99.4%	$41.5M-82.9%	$242.7M+79994.1%	$303K-99.6%	$76.9M+596.6%	$11.0M-82.8%	$64.4M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$19.8M+25.6%	-$21.5M+15.4%	-$20.9M+13.2%	-$22.3M-1.4%	-$26.6M-13.7%	-$25.4M-11.2%	-$24.1M-2.6%	-$22.0M-3.6%
Depreciation & Amortization	$1.2M-25.0%	$1.3M-16.1%	$1.5M-9.2%	$1.6M0.0%	$1.6M0.0%	$1.6M-3.1%	$1.6M-3.9%	$1.6M0.0%
Stock-Based Compensation	$1.4M-51.7%	$1.3M-59.0%	N/A	$2.5M-63.2%	$2.9M-51.7%	$3.2M-44.0%	N/A	$6.8M+22.3%
Capital Expenditures	$202K+329.8%	$37K-97.5%	-$10K-94.3%	$209K-47.9%	$47K-84.4%	$1.5M+524.3%	$176K+29.4%	$401K-55.7%
Free Cash Flow	-$20.0M+24.9%	-$21.5M+19.9%	-$20.9M+13.8%	-$22.5M-0.5%	-$26.7M-12.5%	-$26.9M-16.5%	-$24.3M-2.8%	-$22.4M-1.2%
Investing Cash Flow	$16.7M-49.5%	$18.9M+759.9%	-$44.5M-101.3%	$16.8M+117.4%	$33.0M+11011.6%	-$2.9M-1097.1%	-$22.1M-16164.7%	-$96.6M-10560.2%
Financing Cash Flow	$58K-78.3%	-$65K+37.5%	$75.2M+54813.9%	-$150K	$267K+30.9%	-$104K-100.1%	$137K+80.3%	$0+100.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

ACET Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ACET quarterly financial ratios

Metric	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K
Return on Equity	-73.4%-10.6pp	-62.8%+21.1pp	-83.8%-60.0pp	-23.9%-3.4pp	-20.4%+13.0pp	-33.4%	N/A	N/A	N/A
Return on Assets	-60.7%-7.5pp	-53.2%+15.6pp	-68.8%-47.7pp	-21.1%-2.8pp	-18.3%+5.5pp	-23.8%+10.6pp	-34.5%-26.0pp	-8.5%+52.7pp	-61.2%
Current Ratio	7.47-1.8x	9.29+0.9x	8.41-4.8x	13.25-4.1x	17.31+12.8x	4.46+0.1x	4.32-14.8x	19.16+9.1x	10.02
Debt-to-Equity	0.210.0x	0.180.0x	0.22+0.1x	0.130.0x	0.12-0.3x	0.40	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-17.8%+5.6pp	-14.4%+3.0pp	N/A	-24.6%-10.2pp	-23.4%-10.7pp	-17.5%-6.7pp	N/A	-14.4%+11.2pp
Return on Assets	-14.4%+4.7pp	-11.9%+2.8pp	N/A	-19.1%-6.7pp	-19.1%-8.0pp	-14.8%-5.2pp	N/A	-12.4%+9.0pp
Current Ratio	6.71-0.8x	7.66-1.7x	7.47-1.8x	5.62-5.0x	7.48-5.3x	9.34-5.0x	9.29+0.9x	10.64+1.2x
Debt-to-Equity	0.230.0x	0.210.0x	0.210.0x	0.29+0.1x	0.22+0.1x	0.18+0.1x	0.180.0x	0.160.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Adicet Bio, Inc. ACET	FY2025	N/A	-$116.8M	N/A	$58.5M	—
Immix Biopharma, Inc. IMMX	FY2025	N/A	-$29.4M	N/A	$839.8M	—
MiNK Therapeutics, Inc. INKT	FY2025	N/A	-$12.5M	N/A	$62.3M	—
Cue Biopharma, Inc. CUE	FY2025	$27.5M	-$26.6M	-96.9%	$177.0M	63/100
Cel-Sci Corporation CVM	FY2025	N/A	-$25.4M	N/A	$42.6M	—

Where Adicet Bio, Inc. Ranks

Frequently Asked Questions

Is Adicet Bio, Inc. profitable?

No, Adicet Bio, Inc. (ACET) reported a net income of -$116.8M in fiscal year 2025.

What is Adicet Bio, Inc.'s EBITDA?

Adicet Bio, Inc. (ACET) had EBITDA of -$115.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Adicet Bio, Inc.'s return on equity (ROE)?

Adicet Bio, Inc. (ACET) has a return on equity of -73.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Adicet Bio, Inc.'s free cash flow?

Adicet Bio, Inc. (ACET) recorded an outflow of $97.0M in free cash flow during fiscal year 2025. This represents a -3.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Adicet Bio, Inc.'s operating cash flow?

Adicet Bio, Inc. (ACET) recorded an outflow of $95.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Adicet Bio, Inc.'s total assets?

Adicet Bio, Inc. (ACET) had $192.4M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Adicet Bio, Inc.'s capital expenditures?

Adicet Bio, Inc. (ACET) invested $1.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Adicet Bio, Inc. spend on research and development?

Adicet Bio, Inc. (ACET) invested $99.1M in research and development during fiscal year 2025.

How many shares does Adicet Bio, Inc. have outstanding?

Adicet Bio, Inc. (ACET) had 10M shares outstanding as of fiscal year 2025.

What is Adicet Bio, Inc.'s current ratio?

Adicet Bio, Inc. (ACET) had a current ratio of 7.47 as of fiscal year 2025, which is generally considered healthy.

What is Adicet Bio, Inc.'s debt-to-equity ratio?

Adicet Bio, Inc. (ACET) had a debt-to-equity ratio of 0.21 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Adicet Bio, Inc.'s return on assets (ROA)?

Adicet Bio, Inc. (ACET) had a return on assets of -60.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Adicet Bio, Inc.'s P/E ratio?

Adicet Bio, Inc. (ACET) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $58.5M as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Adicet Bio, Inc.'s price-to-sales ratio?

Adicet Bio, Inc. (ACET) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $58.5M as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Adicet Bio, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Adicet Bio, Inc. (ACET) held $158.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $95.2M over that year. Dividing the one by the other, the reported balance equals about 20 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Adicet Bio, Inc.'s Piotroski F-Score?

Adicet Bio, Inc. (ACET) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Adicet Bio, Inc.'s earnings high quality?

Adicet Bio, Inc. (ACET) reported a net loss of $116.8M while operations used $95.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Adicet Bio, Inc. cover its interest payments?

Adicet Bio, Inc. (ACET) reported an operating loss of $122.1M against $36K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.